23 April 2024 in Cancer Gene Therapy
13 December 2021 in Journal of Neurosurgery: Case Lessons
BACKGROUND: Robotic technology is increasingly used in neurosurgery. The authors reported a new technique for fence-post tube placement using robot-guided frameless stereotaxic technology with neuronavigation in patients with glioma. OBSERVATIONS: Surgery was performed using the StealthStation S8 linked to the Stealth Autoguide cranial robotic guidance platform and a high-resolution three-dimensional (3D) surgical microscope. A surgical plan was created to determine the removal area using fence-post tube placement at the tumor and normal brain tissue boundary. Using this surgical plan, the robotic system allowed quick and accurate fence-post tube positioning, automatic alignment of the needle insertion and measurement positions in the brain, and quick and accurate puncture needle insertion into the brain tumor. Use of a ventricular drainage tube for the outer needle cylinder allowed placement of the puncture needle in a single operation. Furthermore, use of a high-resolution 3D exoscope allowed the surgeon to simultaneously view the surgical field image and the navigation screen with minimal line-of-sight movement, which improved operative safety. The position memory function of the 3D exoscope allowed easy switching between the exoscope and the microscope and optimal field of view adjustment. LESSONS: Fence-post tube placement using robot-guided frameless stereotaxic technology, neuronavigation, and an exoscope allows precise glioma resection.
8 September 2022 in Cancer Gene Therapy
3 March 2025 in Journal of Neurosurgery: Case Lessons
BACKGROUND: Advances in cancer genome analysis technology have made individual cancer genome profiling (CGP) possible. CGP can indicate the presence of hereditary tumors, which are caused by germline pathogenic variants in oncogenes or tumor suppressor genes; if a hereditary tumor is suspected, multigene panel testing (MGPT) is performed. Genomic medicine thus plays an important role in diagnosing hereditary tumors. OBSERVATIONS: A 41-year-old man presented with headache and depressive symptoms. Close examination revealed a mass lesion with cystic components in the right parietal lobe. The tumor was removed via craniotomy and was pathologically diagnosed as a high-grade glioma. CGP of the tumor area revealed a high tumor mutation burden and multiple presumed germline pathogenic variants. MGPT of peripheral blood detected a germline pathogenic variant in MSH6 . The patient was therefore diagnosed with Lynch syndrome. LESSONS: Family history and genetic risk assessments, including CGP, are important for diagnosing genetic diseases. Next-generation sequencing technology is essential for genetic analyses, and if many genetic mutations are identified using tumor-only CGP, MGPT of peripheral blood is an efficient option. In addition, MSH6 variant analysis is important for diagnosing Lynch syndrome and determining treatment. In particular, functional analysis of somatic variants is essential for understanding disease associations. https://thejns.org/doi/10.3171/CASE24718
14 August 2026 in Cancer Gene Therapy